Table 3.
Concomitant laxative use in fixed-dose Phase III studies in OAB patients
| Darifenacin 7.5 mg/day | Darifenacin 15 mg/day | Tolterodine 4 mg/day | Placebo | |
|---|---|---|---|---|
| All patients | ||||
| N | 337 | 334 | 223 | 388 |
| Using laxatives at baseline (%) | 9 (2.7) | 13 (3.9) | 8 (3.6) | 15 (3.9) |
| Using laxatives during trial (%) | 20 (5.9) | 32 (9.6) | 23 (10.3) | 24 (6.2) |
| Patients with constipation | ||||
| N (%) | 50 (14.8) | 71 (21.3) | 28 (12.6) | 24 (6.2) |
| Using laxatives at baseline (%) | 2 (4.0) | 4 (5.6) | 1 (3.6) | 0 (0) |
| Using laxatives during trial (%) | 11 (22.0) | 22 (31.0) | 16 (57.1) | 6 (25.0) |
| Patients with no constipation | ||||
| N (%) | 287 (85.2) | 263 (78.7) | 195 (87.4) | 364 (93.8) |
| Using laxatives at baseline (%) | 7 (2.4) | 9 (3.4) | 7 (3.6) | 15 (4.1) |
| Using laxatives during trial (%) | 9 (3.1) | 10 (3.8) | 7 (3.6) | 18 (4.9) |
Abbreviation: OAB, overactive bladder.